Sodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Cardiotoxicity?

Sodium Glucose Transporter-2 (SGLT2) Inhibition to Prevent Chemotherapy Induced Cardiotoxicity? Dr RR Baliga's 'Got Knowledge Doc' PodKasts for Physicians References Scafoglio C, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015 Scafoglio CR,  et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018 Martinez CA, Scafoglio C. Heterogeneity of Glucose Transport in Lung Cancer. Biomolecules. 2020 Paternostro G, Camici PG, Lammerstma AA, Baliga RR, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest. 1996;98(9):2094‐2099. Bassi NS, Ziaeian B, Yancy CW, Fonarow GC. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure [published online ahead of print, 2020 May 6]. JAMA Cardiol. 2020 Fang JC. Heart-Failure Therapy - New Drugs but Old Habits?. N Engl J Med. 2019 McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995‐2008.